Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios

Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. T...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2022-10, Vol.11 (S1), p.3-4
Main Authors: Zafón, Carles, Castelo, Beatriz
Format: Article
Language:English
Subjects:
Cancer therapies
Disease
Hypertension
Iodine
Localization
Metastasis
Research funding
Thyroid cancer
Transplants & implants
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. The objective of this publication is to review the current knowledge on the use of targeted therapy and the specific practical considerations concerning lenvatinib in the treatment of patients with differentiated thyroid cancer under special circumstances.
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.5154